Therapeutic impact of [18F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain

Skeletal Radiology

Volumn 39, Issue 10, 2010, Pages 987-997

  Fischer, Dorothee Rita ^a   Maquieira, Gerardo J ^b   Espinosa, Norman ^b   Zanetti, Marco ^b   Hesselmann, Rolf ^a   Johayem, Anass ^a   Hany, Thomas F ^a   Von Schulthess, Gustav K ^a   Strobel, Klaus ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

18 F fluoride PET CT; Fluoride uptake; Foot pain; Therapeutic impact

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; FOOT DISEASE; FOOT PAIN; HUMAN; IMAGE ANALYSIS; MALE; METATARSAL BONE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PERIOSTITIS; PLANTAR FASCIITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TENDINITIS; TIBIA; TREATMENT RESPONSE;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; FOOT; FOOT DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBSERVER VARIATION; PAIN; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77957857172     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-010-0875-7     Document Type: Article

References (24)

1. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68-78.
2. Groves AM, Win T, Haim SB, Ell PJ. Non-(18F)FDG PET in clinical oncology (review). Lancet Oncol. 2007;8:822-30. (Pubitemid 47308671)
3. Even-Sapir E, Mishani E, Flusser G, Metser U. 18F-fluoride positron emission tomography and positron emission tomography/ computed tomography. Semin Nucl Med. 2007;37:462-9. (Pubitemid 47505220)
4. Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381-9. (Pubitemid 29368236)
5. Schirrmeister H, Glatting G, Hetzel J, Nüssle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800-1. (Pubitemid 34016348)
6. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287-97. (Pubitemid 46780894)
7. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766-74.
8. Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623-9. (Pubitemid 29471151)
9. Brenner W, Vernon C, Conrad EU, Eary JF. Assessment of the metabolic activity of bone grafts with 18F-fluoride PET. Eur J Nucl Med Mol Imaging. 2004;31:1291-8. (Pubitemid 39222493)
10. Frost ML, Blake GM, Park-Holohan S-J, Cook GJR, Curran KM, Marsden PK, et al. Long-term precision of 18F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism. J Nucl Med. 2008;49:700-7.
11. Sterner T, Pink R, Freudenberg L, Jentzen T, Quitmann H, Bockisch A, et al. The role of [18F]fluoride positron emission tomography in the early detection of aseptic loosening of total knee arthroplasty. Int J Surg. 2007;5:99-104. (Pubitemid 46590857)
12. Ovadia D, Metser U, Lievshitz G, Yaniv M, Wientroub S, Even-Sapir E. Back pain in adolescents: assessment with integrated 18F-fluoride positron-emission tomography-computed tomography. J Pediatr Orthop. 2007;27:90-3. (Pubitemid 46045701)
13. Sörensen J, Michaelsson K, Strand H, Sundelin S, Rahme H. Longstanding increased bone turnover at the fixation points after anterior cruciate ligament reconstruction: a positron emission tomography (PET) study of 8 patients. Acta Orthop. 2006;77:921-5. (Pubitemid 46269199)
14. Dasa V, Adbel-Nabi H, Anders MJ, Mihalko WM. F-18 fluoride positron emission tomography of the hip for osteonecrosis. Clin Orthop. 2008;466:1081-6.
15. Rüdisüli A, Müller-Brand J. Spectrum of findings in SPECT-CT of the feet-a review of 54 patients with pain as the main referring symptom. Supplementum 47 Swiss Medical Forum. 10th Annual Congress of the Swiss Society Of Nuclear Medicine; 4-6 June 2009;9:21-2
16. Pagenstert GI, Barg A, Leumann AG, Rasch H, Müller-Brand J, Hintermann B, et al. SPECT-CT imaging in degenerative joint disease of the foot and ankle. J Bone Joint Surg Br 2009;91:1191-6.
17. Perkins A, Hilson A, Hall J. Global shortage of medical isotopes threatens nuclear medicine services. BMJ. 2008;337:a1577.
18. Stafford N. Isotope shortage is limiting nuclear medicine across Europe. BMJ. 2008;337:a1575.
19. Pneumaticos SG, Chatziioannou SN, Hipp JA, Moore WH, Esses SI. Low back pain: prediction of short-term outcome of facet joint injection with bone scintigraphy. Radiology. 2006;238:693-8.
20. Zafra M, Ayala F, Gonzalez-Billalabeitia E, Vicente E, Gonzalez-Cabezas P, Garcia T, et al. Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of medical oncology patients. Eur J Cancer. 2008;44:1678-83.
21. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991;11:88-94.
22. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and F-18-fluoride whole body PET: a feasible two-in-one approach to cancer imaging? Radiology. 1998;209:253-8
23. Hetzel M, Arslandemir C, König HH, Buck AK, Nüssle K, Glatting G, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003;18:2206-14. (Pubitemid 37463314)
24. Krug B, Van Zanten A, Pirson AS, Crott R, Borght TV. Activity-based costing evaluation of a 18F-fludeoxyglucose positron emission tomography study. Health Policy. 2009;92:234-43.